Biotech Values

[genisi]

Perhaps MNTA shares' recent underperformance may be due to surveys of the MS market showing Copaxone trice-weekly launch is going well and that Teva's estimation that they can switch more than 30% before patent expires and up to 50% this year, sounds more realistic.